Mabwell Biopharma and Shenshi Technology have reached a strategic cooperation to build a large model platform for biopharmaceutical R&D

May 19, 2025  Source: drugdu 80

"/On May 14, Mabwell Biotech and Shenshi Technology jointly announced a strategic cooperation. Both parties will give full play to their respective strengths in biopharmaceutical research and development and artificial intelligence.(AI) big model advantages, jointly build a big model platform for biopharmaceutical R&D, and jointly build innovative drugs Develop a new paradigm.

Mabwell Biopharma has outstanding advantages in the construction of ADC technology platforms and the discovery of single/double antibody molecules, and has opened up the entire industry chain of ADC drugs from research and development to production. The independently developed IDDC platform and Mtoxin toxin technology have been verified in many projects. Shenshi Technology has built a complete microscopic world cognition and computing system with its independently developed Uni-Smart scientific literature multimodal model, Uni-Mol molecular conformation model and Uni-Fold protein folding model and other series of life science models. The two parties will cooperate in two directions: First, knowledge engine construction, relying on the Uni-SMART multimodal scientific literature model to build a knowledge engine for innovative biological drug research and development, to achieve accurate intelligent screening of scientific literature, identification and extraction of multimodal elements, and to achieve all-round and in-depth analysis and interpretation, thereby building a rich and reliable target database, significantly improving research efficiency, and accelerating the analysis and development process; second, innovative target exploration, RiDYMO® high-quality Hit discovery and optimization platform, can unlock the kinetic mechanism of difficult-to-drug targets and explore a wider range of molecular chemical space. Its core algorithm, enhanced dynamics RiD, can increase the sampling efficiency of molecular simulation by nearly 100 times, effectively capturing the dynamic conformational changes of biological macromolecules. The cooperation will integrate the advantages of Mabwell Bio's ADC technology and Deepin's RiDYMO® platform to jointly explore breakthroughs in innovative target mechanism research and accelerate the discovery of drug molecules from 0 to 1.

https://finance.eastmoney.com/a/202505143404438241.html

By editor
Share: 

your submission has already been received.

OK

Subscribe

Please enter a valid Email address!

Submit

The most relevant industry news & insight will be sent to you every two weeks.